Kindred Biosciences to Provide Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

San Francisco, CA (January 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016. Read more

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates

KIND-012 study meets primary endpoint with p<0.0001. Data to be filed with the FDA for approval. SentiKind study misses primary endpoint.

Conference call and webcast scheduled for 5:00 p.m. Eastern Time today.

San Francisco, CA (November 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses. Read more

Kindred Biosciences to Present at 2015 Jefferies Animal Health Summit

San Francisco, CA (March 19, 2015) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will be presenting at the 2015 Jefferies Animal Health Summit in New York, NY on Thursday, March 26, 2015 at 1:30 PM EDT.

Read more

KindredBio to Present at Jefferies 2014 Global London Healthcare Conference

SAN FRANCISCO, California. (November 17, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting at the 2014 Jefferies Global Healthcare Conference in London on Thursday, November 20, 2014 at 5:00 PM GMT. Read more

Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis Conference Call

Wednesday, August 20, 2014
Time of call: 5:30pm ET/ 2:30pm PST

Participant Toll-free Dial-in number: (855) 433-0927
Participant International Dial-in number: (484) 756-4262
Conference ID: 91627369

KindredBio to Host Investor Breakfast on June 13 in New York City

SAN FRANCISCO, California. (June 11, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will host an Investor Breakfast on Friday, June 13, 2014 in New York City. KindredBio’s executive management team will provide an overview of the Company’s strategies and Stephen Sundlof, D.V.M, Ph.D., will offer insights into the animal health business from an FDA perspective.

Read more

KindredBio to Present at Craig-Hallum, Stifel, and Jefferies Conferences

SAN FRANCISCO, California. (May 21, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will participate in the 11th Annual Craig-Hallum Institutional Investor Conference in Minneapolis on May 28th. KindredBio will present at the Stifel Dental and Veterinary Conference on May 28th and the Jefferies Global Healthcare Conference on June 2nd, both in New York City. Details for the presentations are below:

Read more

KindredBio to Present at Needham 13th Annual Healthcare Conference

SAN FRANCISCO, California. (April 4, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Needham 13th Annual Healthcare Conference in New York City:

Read more

KindredBio to Present at Roth Capital Partners 26th Annual Growth Stock Conference

SAN FRANCISCO, California. (March 4, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26th Annual Growth Stock Conference in Dana Point, CA:

Read more

KindredBio to Present at 2014 Leerink Global Healthcare Conference

SAN FRANCISCO, California. (February 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that members of its senior management team will participate in a fireside chat presentation at the 2014 Leerink Global Healthcare Conference in New York City:

Read more